A 59-year-old female was admitted to our hospital due to PE, aggravated by chest tightness and shortness of breath for 1 week. PE was treated using AngioJet and inferior vena cava filter implantation under general anesthesia.

Six months ago, the patient was hospitalized for meningeal metastasis of lung cancer for more than one month, wheezing for three days, and aggravation of wheezing for one day. On examination, she was found to have PE that was treated with alteplase, followed by low-molecular weight heparin for anticoagulation, and continued anticoagulation for four months after discharge. Two months ago, the patient discontinued the anticoagulation therapy on her own, and one week ago, she experienced chest tightness and shortness of breath, with significantly decreased activity endurance, which progressively aggravated.

Thoracoscopic left upper lobe resection was performed for lung cancer three years ago, and targeted drug therapy was provided after operation. Eight months ago, the patient was hospitalized nine times for symptoms associated with meningeal cancer, underwent lumbar puncture, and was administered intrathecal injections of methotrexate several times. The patient had a history of hypertension of more than 10 years, with a normal blood pressure of 140/100 mmHg. She underwent hysteromyomectomy 14 years ago.

The patient’s father died of lung cancer at the age of 60 years, and her mother died of coronary heart disease at the age of 57 years.

On physical examination, the patient had a body temperature of 36.5°C, heart rate of 106 times/min, respiratory rate of 18 times/min, and blood pressure of 109/82 mmHg; her height was 159 cm, weight was 70 kg, and body mass index was 27.7 kg/m². The patient was brought to the ward on a stretcher, with good consciousness and low spirit. The patient was uncooperative during the physical examination, which revealed fine moist rales in both lungs, tachycardia (the fastest was approximately 130 beats/min), and no edema in the lower limbs.

Laboratory test results showed the following values: electrolytes: blood sodium 134 mmol/L (137-147 mmol/L) and blood potassium 5.4 mmol/L(3.5-5.3 mmol/L); liver and kidney functions: glucose 7.75 mmol/L(3.9-6.1 mmol/L) and creatinine 77 umol/L(41-73 umol/L); coagulation tests: B-type natriuretic peptide precursor 9810.00 ng/L(0-125 ng/L), prothrombin time 13.0 s(9.4-12.5 s), D-dimer 2.256 mg/L(<0.243 mg/L), and fibrinogen degradation product 11.81 mg/L(<5.00 mg/L). Troponin I and myoglobin levels were within the normal range. Other laboratory tests showed no obvious abnormality.

Chest computed tomography (CT) showed PE in both lungs, postoperative changes in the left lung, a little chronic inflammation in the middle lobe of the right lung, and bullae in the upper lobe of the right lung.

Computer tomography angiography of the pulmonary artery showed that there were strip-filling defects in both pulmonary trunks, which spanned the left and right pulmonary trunks, and filling defects were found in the pulmonary lumens of each lobe of both lungs. The inner diameter of the main pulmonary artery was approximately 37 mm, the width of the left pulmonary artery trunk was approximately 19 mm, and the width of the right pulmonary artery trunk was approximately 21 mm ( Figure 1 ).

Color Doppler echocardiography showed that the pulmonary pressure revealed a slight-to-moderate increase, with a small amount of tricuspid regurgitation and an enlarged right heart (–signs of right heart strain). Other related parameters were as follows: transverse diameter of right atrium: 43 mm, anteroposterior diameter of right ventricle: 29 mm, estimated mean pulmonary artery pressure: 51 mmHg, left ventricular ejection fraction: 68%, stroke output: 31 mL/stroke, heart rate: 111 beats/min, and output per minute: 3.5 L/min.

Ultrasonography of lower extremity veins revealed a heterogeneous echo on the inner wall of the right superficial femoral vein, which was suspected to be a wall thrombus and a heterogeneous echo in the right popliteal vein, posterior tibial vein, and calf muscle veins, which were suspected to be due to thrombosis.

Electrocardiogram(ECG) revealed sinus tachycardia (107 beats/min) with right ventricular hypertrophy and nonspecific T wave abnormality. There was a “S1Q3T3” pattern- McGinn-White Sign.

Acute right heart failure caused by pulmonary spasm during PE and embolectomy.

Routine monitoring was initiated as the patient was brought into the operating room at 14:25. The patient’s invasive radial arterial blood pressure was 130/78 mmHg, her heart rate was 101 beats/min, her pulse oximetry was 94% (4 L/min of oxygen inhalation), and arterial blood gas analysis revealed a partial pressure of oxygen (PO₂) of 109.6 mmHg and partial pressure of carbon dioxide (PCO₂)of 32.9 mmHg. The patient was administered 0.1 µg/kg/min of norepinephrine before anesthesia induction, and anesthesia induction was initiated at 14:40. The patient was intravenously injected 7 mg etomidate, 15 µg sufentanil, and 50 mg rocuronium. Following 2 min, a 7.5^#single-lumen tracheal tube was successfully inserted via the mouth. After successful tracheal intubation, a double-lumen central venous catheter was inserted through the right internal jugular vein. The operation began at 15:20. The left femoral vein was punctured and inserted with a short 8F sheath. The patient was administered 5000 IU of heparin sodium and 10 mg of dexamethasone. The left iliofemoral vein and inferior vena cava were unobstructed by hand radiography. A Misgurnus anguillicaudatus guide wire with a single curved catheter was passed through the tricuspid valve to the pulmonary artery trunk, and the pig tail catheter was replaced. High-pressure angiography revealed that the left pulmonary artery had a banded thrombus and the right lower lobe artery was occluded ( Figure 2 ). A catheter guide wire was inserted into the right lower lobe artery to replace the supercore guide wire, and an AngioJet solent catheter (Specification Model: SOLENT omni, Boston Scientific Corporation, Two Scimed Place, Maple Grove, Mn USA 55311) was inserted into the inferior lobe artery of the pulmonary artery. Further, 150,000 IU of urokinase was administered for thrombolysis at 16:10. Five seconds later, the patient’s blood pressure dropped to 80/50 mmHg, and her heart rate increased to 123 beats/min. The pump speed of norepinephrine was adjusted to 0.3 µg/kg/min. After administration of 100 mL of compound sodium acetate ringer’s solution, the heart rate increased to 130 beats/min and blood pressure was 83/60 mmHg. Considering cardiac insufficiency, 10 µg/kg/min dopamine was administered following which the heart rate increased to 142 beats/min and blood pressure was 80/60 mmHg. There was no obvious improvement after administering the pressor drugs. A filter was placed in the inferior vena cava, and the sheath was withdrawn. The patient’s blood pressure dropped to 60/30 mmHg, and the percutaneous pulse oxygen saturation dropped to 80%. At 16:35, cardiac compressions were initiated, 1 mg/3 min epinephrine was administered, dopamine was stopped, 0.3 µg/kg/min adrenaline was initiated, 1.2 µg/kg/min norepinephrine was pumped, and 190 mL of 5% sodium bicarbonate was administered thrice. The vasoactive drugs adrenaline (0.3 µg/kg/min) and norepinephrine (1.2 µg/kg/min) were administered with blood pressure at 152/100 mmHg, heart rate 149 beats/min, and arterial oxygen partial pressure at 206 mmHg. At 17:45, the patient was returned to the ward with tracheal intubation. The total anesthesia time was 180 min, operation time was 70 min, and rescue time was 62 min (including cardiopulmonary resuscitation for 37 min); 600 mL crystalloid solution was infused, and urine volume was 0 mL. Arterial blood gas analysis was performed intermittently during the perioperative period ( Table 1 ).

This study reports a case of PE in which a patient with meningeal metastasis of lung cancer discontinued anticoagulants without consulting the prescriber. Her pulmonary embolism severity index score is 149, with a grade of 5, indicating extremely high risk, with a 30-day mortality risk of 10-24.5%, hence, the patient was diagnosed with high-risk PE.

The patient’s PE treatment plan was tailored to her specific clinical needs. Due to her meningeal metastasis potentially compromising the blood-brain barrier, she faced a significantly increased risk of intracranial hemorrhage (up to 10-20%), making systemic thrombolysis inappropriate. After weighing the risks of thrombosis and bleeding, the Multidisciplinary Team (MDT) decided on a treatment approach involving pigtail catheter mechanical fragmentation, local thrombolysis, and AngioJet PE removal. This approach effectively and swiftly cleared the fresh clots within the pulmonary arteries, restored hemodynamic stability, and reduced the risk of bleeding. Since patients with malignancies are often in a hypercoagulable state and have a high incidence of thrombotic events, studies indicate that the risk of PE in cancer patients can be up to four times higher than in the general population (5). For such patients, long-term anticoagulation with LMWH is recommended (6). The suggested LMWH dose is 100 IU/kg every 12 hours (6). LMWH provides consistent anticoagulation without the need for frequent monitoring, making it particularly suitable for patients who may have difficulty adhering to complex medication regimens. Consequently, for this patient, the chosen long-term anticoagulation regimen was a subcutaneous injection of 6000 IU of LMWH every 12 hours.

The AngioJet Thrombectomy System is a pharmacomechanical peripheral thrombectomy device with active aspiration and Power Pulse™ lytic delivery designed to treat the widest range of thrombosed vessels, rapidly restoring blood flow. Its mechanism of action is as follows. The AngioJet console energizes the pump which sends pressurized saline to the catheter tip; Saline jets travel backwards to create a low pressure zone causing a vacuum effect; Thrombus is drawn into the in-flow windows and the jets push the thrombus back down the catheter; Thrombus is evacuated from the body and into the collection bag. The AngioJet Thrombectomy System is used to break apart and remove thrombus from peripheral arteries and veins ≥ 3.0mm in diameter. The Thrombectomy Set has not been evaluated for treatment of PE. It poses a challenge for anesthesiologists. The patient had circulatory instability or even circulatory failure, which was complicated with conditions such as pulmonary hypertension, hypoxemia, pulmonary lobectomy, meningeal cancer. Considering her high-risk PE status and underlying malignancy, the MDT chose AngioJet thrombectomy combined with local thrombolysis. This approach allowed targeted treatment of the thrombus, effectively reducing exposure to systemic thrombolytics and minimizing the risk of serious bleeding complications.

Prompt and accurate identification of pulmonary artery spasm and effective intervention are crucial first steps in resuscitation ( Table 2 ). The occurrence of pulmonary artery spasm is closely related to mechanical stimulation from catheters, pressure fluctuations, and endothelial reactions triggered by thrombus disruption. The surgical procedures such as pig tail catheter placement, high-pressure syringe angiography, AngioJet solent catheter embolectomy, and urokinase thrombolysis may induce pulmonary artery spasm in patients (7, 8). The mechanical procedure, sudden aggravation of right heart failure, and stabilization of the circulation after symptomatic treatment support the diagnosis of acute right heart failure caused by pulmonary artery spasm in this patient. At that time, the patient’s vital signs were unstable, and the situation was critical. Considering the urgency of the situation, symptomatic treatment was initiated to rescue the patient, and pulmonary angiography, which could have clarified the cause of circulatory and respiratory failure in this patient, was not performed. Upon suspecting pulmonary artery spasm, surgical procedures should be immediately halted to prevent further mechanical stimulation. Additionally, low-dose inhaled nitric oxide (NO) and administration of prostaglandins can be considered to alleviate the spasm and reduce pulmonary hypertension.

Understanding the pathophysiological mechanisms behind circulatory failure and implementing prompt supportive treatments are crucial in resuscitation. Pulmonary artery spasm can lead to increased pulmonary vascular resistance and elevated right ventricular afterload, triggering acute right heart failure. Acute dilation of the right ventricle causes the interventricular septum to shift leftward, compressing the left ventricle, restricting its filling, and reducing cardiac output. Simultaneously, a reduction in pulmonary circulation volume, a rapid decrease in left ventricular preload, and diminished cardiac output result in refractory hypotension. Hypoxemia and acidosis further exacerbate pulmonary hypertension, creating a vicious cycle that worsens right heart function, aggravates hypotension, and leads to inadequate tissue perfusion. Insufficient cardiac output caused by acute right heart failure is the primary cause of death in patients with acute PE. During the resuscitation of this patient, active chest compressions, correct vasoactive drugs, and adequate anticoagulation and thrombolysis were the key to successful resuscitation ( Table 3 ). The circulatory support treatment plan is as follows: (1) Careful Fluid Resuscitation. Clinical evidence shows that active volume expansion is not only useless, but may worsen the right heart function due to excessive mechanical stretching or reflex mechanism inhibiting myocardial contractility (9); therefore, the symptoms of right heart failure are aggravated after fluid replacement treatment. (2) Choice of Vasopressor Agents: At this time, supportive treatment with vasoactive drugs is extremely important. Norepinephrine can improve the right ventricular function through direct positive inotropic effect and simultaneously improve the systemic blood pressure by stimulating peripheral vascular α receptor and the right ventricular coronary perfusion. Epinephrine has the advantages of both norepinephrine and dobutamine, but has no vasodilating effect of systemic circulation, which may be beneficial for patients with acute PE and shock. Dobutamine and dopamine are beneficial for patients with acute PE with low cardiac index and normal blood pressure; however, caution must be exercised as they can lead to further redistribution of blood flow from blocked blood vessels to unblocked blood vessels, thus aggravating the imbalance of ventilation/blood flow ratio. (3) The Role and Potential Risks of Chest Compressions: Chest compressions not only assist cardiac ejection during cardiopulmonary resuscitation, but also break large thrombi in pulmonary arteries into small thrombi due to the associated mechanical stimulation, thus relieving the thrombus load of pulmonary artery trunk. Need to acknowledge that the detachment of smaller thrombi into the systemic circulation poses a potential risk of stroke in the future. In future cases, adjunctive anticoagulant therapy and thromboprophylactic techniques, such as pulmonary artery filters, may help capture embolic fragments, reducing the risk of small thrombi entering the systemic circulation and thus lowering the incidence of complications like stroke. (4) Extracorporeal membrane oxygenation (ECMO) as a Bridge to Recovery: ECMO is helpful for high-risk PE to maintain the circulation and oxygenation of important organs during acute right heart failure and cardiogenic shock. ECMO support combined with anticoagulation therapy can be used as a bridge to surgery or percutaneous pulmonary embolectomy. An expert group agreed that the best treatment choice of ECMO for PE patients should be individualized according to the multidisciplinary approach (10).

In cancer-associated PE patients, long-term anticoagulation is crucial for preventing thrombus recurrence. For patients with incurable malignancies, lifelong anticoagulation may be necessary. In cancer-associated PE cases with a high risk of bleeding, LMWH is preferred over direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) due to its superior efficacy in reducing thrombus recurrence and minimizing the risk of major bleeding (11). The recommended dosage is 100 IU/kg administered every 12 hours, with a duration ranging from six months to lifelong treatment (12). To address the patient’s history of discontinuing anticoagulation therapy, additional measures were implemented to enhance her adherence. Comprehensive education for both the patient and her family was emphasized, providing detailed explanations about the importance of anticoagulation therapy and the risks associated with inconsistent medication use. A personalized dosing schedule, tailored to her daily routine (administering low-molecular-weight heparin subcutaneously at 8 AM and 8 PM), was developed. All abbreviations used in this study are listed in Table 4 for reference. This was supplemented by family reminders or phone alarms. Furthermore, weekly follow-up calls by the medical team were conducted to monitor compliance and offer encouragement. This approach aimed to establish a support system centered on patient self-discipline, family involvement, and consistent medical guidance.

To prevent further thrombotic events, the MDT recommended placing an inferior vena cava filter during the procedure. After surgery, personalized follow-up is essential, focusing on monitoring anticoagulation adherence, treatment tolerance, and regular imaging to detect any recurrence or progression of thrombus. Follow-up should occur every three to six months, including imaging studies such as echocardiography or CT pulmonary angiography to assess residual thrombi and right heart function. The anticoagulation regimen should be adjusted as needed, based on the patient’s bleeding risk and treatment tolerance, ensuring a careful balance between preventing thrombosis and minimizing bleeding complications.

In this case, the lack of echocardiographic monitoring during the rescue was a notable limitation. Real-time echocardiography is essential during CDT to monitor right heart function and pulmonary artery pressure. However, several practical challenges limit its use in such emergency settings. Many anesthesia departments don’t have dedicated echocardiography equipment, and not all anesthesiologists are trained in its use. In emergencies, such as acute heart failure, time constraints and limited staff can make it difficult to conduct timely cardiac ultrasound assessments. Additionally, transthoracic echocardiography isn’t feasible during chest compressions, and transesophageal echocardiography (TEE) can increase the risk of gastrointestinal bleeding, especially when patients are on anticoagulation with heparin. To overcome these hurdles, close coordination between anesthesia and ultrasound teams is crucial. Designating staff trained in echocardiography for such cases can help speed up assessments. Pre-inserting the TEE probe before giving heparin allows for intermittent monitoring without increasing bleeding risks. If an emergency arises, the designated team member can quickly use the pre-positioned TEE probe for cardiac evaluation, preventing delays. Portable or handheld ultrasound devices, suited for constrained spaces in intervention rooms, provide a practical solution for rapid deployment and monitoring. Regular ultrasound training for anesthesiologists and clear protocols for use in specific scenarios can also help ensure high-quality diagnostic imaging when time is critical.

In this case, NO was not available in the interventional suite, so it was not used to relieve pulmonary artery spasm. NO can be beneficial in such situations as it helps to reduce pulmonary artery pressure and stabilize hemodynamics. For facilities equipped with NO in their operating rooms, its use is recommended as part of the management for pulmonary artery spasm, especially in high-risk patients.